Bristol Myers Squibb Just Gave Away Five Drugs. One Startup Got Them All.

Then there's BMS-986326, an IL-2-CD25 fusion protein designed to boost regulatory T cells (the peacekeepers of your immune system) without juicing the inflammatory ones. It's in Phase 1b testing for atopic dermatitis, which is severe eczema, as well as lupus.

Lomedeucitinib rounds out the clinical-stage trio. It's an oral TYK2 inhibitor being tested in Phase 2 for plaque psoriasis. If that drug class sounds familiar, it should: BMS already has an approved TYK2 inhibitor on the market called Sotyktu. More on that tension in a moment.

Finally, two preclinical biologics targeting IL-10 and IL-18 pathways could enter clinical trials within 12 to 18 months. These are aimed at gastrointestinal inflammatory conditions, broadening Beeline's reach beyond skin and joints.

Why Did BMS Let These Go?

This is the question that makes the whole story interesting. Bristol Myers Squibb is one of the biggest pharma companies on the planet. Why hand off five promising autoimmune programs to a startup?

The answer comes down to focus. BMS is staring down patent cliffs on some of its biggest drugs and needs to concentrate resources on its most advanced assets. Sotyktu, its approved psoriasis therapy, is a commercial priority. Orencia, its rheumatoid arthritis workhorse, needs defending. Running five earlier-stage programs across multiple autoimmune indications is expensive, and big pharma moves slowly.

So BMS did something clever: it spun the assets out to a nimble startup that can move faster, while retaining nearly 20% equity in the new company, plus royalties and milestone payments. It's less of a breakup and more of a "let's see other people but keep texting" arrangement.

This playbook is becoming increasingly common in pharma. Rather than killing programs that don't fit the portfolio or letting them languish in a pipeline backlog, companies spin them into focused biotechs. If the drugs work, the parent company still profits handsomely through equity and milestones. If they don't, someone else absorbed the risk.

The Autoimmune Gold Rush

Beeline is entering a crowded party. Autoimmune disease has become one of the hottest areas in biotech, with over 140 lupus therapies alone in clinical trials from more than 120 companies. Recent approvals like Gazyva for lupus nephritis and FDA Breakthrough designation for litifilimab in cutaneous lupus have only intensified interest.

But most competitors don't launch with $300 million and three clinical-stage programs. Beeline's single financing round matched or exceeded what many well-funded autoimmune biotechs have raised across multiple rounds.

That war chest matters because autoimmune drug development is notoriously expensive and unpredictable. Lupus, in particular, has been a graveyard for clinical trials. The disease is so varied from patient to patient that finding a drug that works broadly enough to satisfy regulators is like trying to design one pair of shoes that fits every foot. Many have tried. Most have failed.

The Lomedeucitinib Question

One wrinkle worth watching: Beeline is developing lomedeucitinib, a TYK2 inhibitor for psoriasis, while BMS still sells Sotyktu, another TYK2 inhibitor for the same disease. BMS actually discontinued a different TYK2 inhibitor (BMS-986322) in February 2025 to prioritize Sotyktu's commercialization.

So why let Beeline run with a competing compound? Possibly because lomedeucitinib has differentiated characteristics, or because BMS sees the psoriasis market as big enough for multiple entries. Or perhaps BMS simply views it as Beeline's problem now, with upside if it works. Either way, it's an unusual dynamic: a startup developing a drug that could compete with its former parent's marketed product, while that parent still owns a chunk of the startup.

What Comes Next

The near-term catalyst is obvious. Afimetoran's Phase 2 lupus data, expected by late 2026, will be the first real test of whether Beeline's pipeline is as promising as its balance sheet. If the results are strong, the company will have one of the most compelling lupus programs in biotech. If they disappoint, $300 million buys a lot of runway, but not infinite patience.

Beeline's headquarters split between Stamford, Connecticut and Boston, Massachusetts puts it squarely in biotech's East Coast corridor. The company plans to push multiple programs into clinical trials over the next 12 months, an ambitious pace that only makes sense with deep pockets and experienced operators.

For now, Beeline Medicines has done something rare: launched with enough money, enough pipeline diversity, and enough leadership credibility to be taken seriously from day one. In biotech, where most startups spend years scraping together funding and hunting for their first drug candidate, that head start is worth more than any single molecule.

The question is whether five hand-me-down programs from Big Pharma can become something bigger than BMS thought they could be. Beeline's entire bet is that the answer is yes.

The Biotech Field That Didn't Exist a Decade Ago Just Got Its Biggest Bet Yet

Storm Therapeutics just raised $56 million and dosed the first patient in a Phase 2 sarcoma trial, all for a drug targeting an enzyme most people have never heard of. It's the biggest clinical milestone yet for epitranscriptomics, a therapeutic field that literally didn't exist a decade ago.